Table 3.
Cox Proportional Hazards Ratio Analyses of Variables in Myelodysplastic Syndrome Harboring SF3B1 Mutations Prognostic of Overall Survival
| Risk Factor | Hazard Ratio | 95% CI | P |
|---|---|---|---|
| Univariate analysis | |||
| Age, <70 vs ≥70 y | 1.80 | 0.38-8.56 | 0.46 |
| Sex, M/F | 1.08 | 0.29-4.03 | 0.91 |
| Hemoglobin, <10 vs ≥10 g/dLa | 3.16 | 0.92-14.69 | 0.095 |
| Neutrophil count, <0.8 vs ≥0.8 × 109/La | 1.04 | 1.01-1.08 | 0.012 |
| Platelet count, <50 vs 50~100 vs ≥100 × 109/La | 3.75 | 0.45-19.34 | 0.19 |
| Bone marrow blast counta | 0.91 | 0.05-5.07 | 0.92 |
| Ring sideroblasts, % | 0.96 | 0.92-1.00 | 0.04 |
| Cytogenetic risks, high/very high vs intermediate/low/very lowa | 4.72 | 0.53-42.40 | 0.17 |
| Number of comutations | 1.26 | 0.74-1.98 | 0.79 |
| SF3B1 VAF. %b | 0.72 | 0.09-8.80 | 0.78 |
| Epigenetic comutationsc | 0.72 | 0.18-2.89 | 0.64 |
| TF comutationsc | 9.67 | 2.23-41.94 | 0.003 |
| IPSS-R score, >3 vs ≤3 | 7.88 | 1.72-35.33 | 0.008 |
| SF3B1-mut-MDS by IWG-PMd | 0.46 | 0.13-1.61 | 0.23 |
| Multivariate analysis | |||
| TF comutationsc | 9.14 | 1.1-76.1 | 0.04 |
| IPSS-R score, >3 vs ≤3 | 5.12 | 1.0-26.1 | 0.049 |
| SF3B1-mut-MDS by IWG-PMd | 1.43 | 0.3-6.76 | 0.64 |
IPSS-R, Revised International Prognostic Scoring System; IWG-PM, International Working Group for the Prognosis of MDS; SF3B1-mut-MDS, SF3B1-mutant myelodysplastic syndrome; TF, transcription factor; VAF, variant allele fraction.
aIPSS-R categories.
bRange hazard ratio.
cPresent vs absent.
dYes vs no.